152121-83-0

Usage

Uses

Used in Pharmaceutical Industry:
Ethanone, 1-(3-methoxyphenyl)-2-(4-pyridinyl)is used as a building block for various drug molecules due to its unique structure. It is particularly valuable in the development of drugs with therapeutic properties, such as those targeting neurological disorders and inflammation.
Used in Drug Discovery and Development:
Ethanone, 1-(3-methoxyphenyl)-2-(4-pyridinyl)is used as a significant compound in drug discovery and development. Its aromatic ring structure allows for further modifications and structure-activity relationship studies, which are crucial in the design and optimization of new drug molecules. This makes it a promising candidate for the creation of novel therapeutic agents.

Upstream product

• 224040-60-2 1-(3-methoxybenzoyl)-2-methylaziridine 
• 108-89-4 picoline 
• 1711-05-3 m-anisoyl chloride 
• 5368-81-0 methyl 3-methoxybenzoate 

Downstream Products

• 224038-76-0 [4-(3-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine 
• 1231737-08-8 2-[1,3]dithietan-2-ylidene-1-(3-methoxy-phenyl)-2-pyridin-4-yl-ethanone 

Relevant academic research and scientific papers

BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS

3,4-diaryl-bicyclicpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invent

Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as selective adenosine A3 antagonists

To investigate the potency of an adenosine A3 receptor (A 3AR) antagonist as an anti-asthmatic drug, a novel series of 4-phenyl-5-pyridyl-1,3-thiazole derivatives was synthesized and evaluated in human adenosine A1, A

Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as p38 MAP kinase inhibitors

A novel series of 4-phenyl-5-pyridyl-1,3-thiazole analogues possessing potent in vitro inhibitory activity against p38 mitogen-activated protein kinase and the release of tumor necrosis factor-α (TNF-α) from human monocytic THP-1 cells stimulated by lipopolysaccharide has been identified. Subsequent structure-activity relationship (SAR) studies and optimization for absorption, distribution, metabolism, and elimination (ADME) profiles led to the identification of compounds 7g and 10b as orally active lead candidates that block the in vivo production of proinflammatory cytokine (TNF-α). In pharmacokinetic studies, compound 10b showed good oral administration in mice and demonstrated significant in vivo anti-inflammatory activity in an anti-collagen monoclonal antibody-induced arthritis mouse model (minimum effective dose (MED)=30 mg/kg). Further elucidation of this class of compounds may provide novel anti-inflammatory agents, such as anti-rheumatoid arthritis drugs.

Adenosine A3 receptor antagonists

A pharmaceutical composition for antagonizing adenosine at adenosine A3receptors which comprises a 1,3-azole compound substituted on the 4- or 5-position, or both, by a pyridyl which may be substituted is provided and can be used as a prophylactic and therapeutic agent for asthma, allergosis, inflammation, and so on.